Cereno Scientific’s expands the patent protection for CS1 in the US
Cereno Scientific (XSAT: CRNO B) today announced that two new patents have been granted in drug candidate CS1’s second and third patent families, respectively, in the US. This strengthens and broadens the intellectual property right (IPR) for Cereno’s Phase II drug candidate CS1 which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).
“We are pleased that our continuous work in securing a strong IPR portfolio has resulted in yet another expansion of CS1’s patent protection. The US is a particularly important market and, thus, the expanded patent protection is a significant milestone with regards to the commercial potential of CS1 and the company,” said Sten R. Sörensen, CEO at Cereno.
This new patent in CS1’s second patent family broadens the protection already granted in the US and, is titled “Valproic Acid for the Treatment or Prevention of Pathological Conditions Associated With Excess Fibrin Deposition and/or Thrombus Formation.” The patent number assigned is US 11,400,064, and will be valid through 2035, with the possibility of patent extension of up to five years. The second patent family has previously been granted in Australia, Europe, Canada and the US.
In CS1’s third family, the patent granted is titled “Delayed Release Pharmaceutical Formulations Comprising Valproic Acid, and Uses Thereof.” The patent number assigned is US 11,395,808, and will be valid through 2037, with the possibility of patent extension of up to five years. Previously, the third patent family has granted patents in Japan and Russia.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.